

**ENANTA Pharmaceuticals, Inc.**

500 Arsenal Street  
Watertown, Massachusetts  
02472

Tel: 617.607.0800  
Fax: 617.607.0530  
www.enanta.com

**FOR IMMEDIATE RELEASE**

**CONTACT:**

Susan Burke, Account Executive  
Ronald Trahan Associates, Inc.  
508-647-9782, ext. 20



**Enanta Pharmaceuticals appoints Andrew M. Slee, Ph.D.,  
as Vice President of Pharmacology**

CAMBRIDGE, Mass., June 6, 2001 -- Enanta Pharmaceuticals Inc., an emerging biopharmaceutical company, announced today the appointment of Andrew M. Slee, Ph.D., as Vice President of Pharmacology, effective immediately.

"With the appointment of Dr. Slee - an outstanding pharmacologist with strong expertise in the management of drug development programs in our target therapeutic areas of anti-infectives and anti-inflammatories - we are now strongly positioned to succeed in these areas," said Dr. Spiros Jamas, Enanta's president and chief executive officer.

"Enanta has unprecedented technology for transforming existing drugs, natural products and peptides into novel small-molecule drugs that are entirely new intellectual properties," said Dr. Slee. "I am, therefore, eager to join the Company and participate in moving its proprietary drug candidates into clinical development."

Prior to joining Enanta Pharmaceuticals, Dr. Andrew Slee was Senior Director of General Pharmacology, Cardiovascular Sciences, Anti-infectives, and Research Administration at DuPont Pharmaceuticals Co., since 1995. From 1985-1995, Dr. Slee held various positions at DuPont Merck Co. These positions included Group Leader of the Chemotherapy and Infectious Diseases Group, Associate Director of Discovery Coordination and Research Administration and also Senior Director of Preclinical Pharmacology and Research Administration. Dr. Slee earned a doctor of science degree in microbiology at Syracuse University, where he was honored with the Alexander Gourevitch Memorial Award in Microbiology.

Enanta Pharmaceuticals, founded in 1998, has raised \$25 million to date in private financings. Investors include: Oxford Bioscience Partners (lead investor),

TVM - Techno Venture Management, Advent International Corporation, Bank Vontobel, Alpinvest International B.V. and KB Lux Venture Capital.

Headquartered in Cambridge, Mass., Enanta Pharmaceuticals is creating its patented Morphed Chemical Entity (MCE™) libraries by transforming existing drugs, natural products and peptides into novel small-molecule drugs. The Company's initial focus is on MCEs derived from existing drugs that address significant unmet medical needs: (a) antibacterial agents (*macrolides* and *ketolides* to overcome bacterial resistance); and (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases. Enanta is also using its proprietary Peptide Morphing™ capability to create improved antiviral drugs for HIV, HCV and HPV.

# # # # #